Last reviewed · How we verify

Mevacor (LOVASTATIN)

Merck & Co. · FDA-approved approved Small molecule

Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.

Mevacor (Lovastatin) is a small molecule HMG-CoA Reductase Inhibitor developed by Merck, targeting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It was FDA approved in 1987 for various indications related to high cholesterol and cardiovascular disease. As an off-patent medication, Mevacor is available from multiple generic manufacturers. Key safety considerations include potential liver damage and muscle pain. Mevacor is used to treat conditions such as hypercholesterolemia, hyperlipidemia, and familial hypercholesterolemia.

At a glance

Generic nameLOVASTATIN
SponsorMerck & Co.
Drug classHMG-CoA Reductase Inhibitor
Target3-hydroxy-3-methylglutaryl-coenzyme A reductase
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1987

Mechanism of action

Lovastatin is lactone that is readily hydrolyzed in vivo to the corresponding -hydroxyacid, strong inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results